安旭生物12月24日获融资买入144.65万元，融资余额9492.49万元

Group 1 - The core viewpoint of the news is that Anxu Bio's financial performance has shown a decline in revenue and net profit, alongside low financing activity and high short-selling levels [1][2]. Group 2 - As of December 24, Anxu Bio's stock price increased by 0.03%, with a trading volume of 12.83 million yuan [1]. - On the same day, the financing buy amount was 1.45 million yuan, while the financing repayment was 2.52 million yuan, resulting in a net financing buy of -1.07 million yuan [1]. - The total financing and securities balance for Anxu Bio reached 94.92 million yuan, which is 1.93% of its market capitalization and below the 40th percentile level over the past year, indicating a low financing position [1]. - In terms of short selling, Anxu Bio had no shares sold or repaid on December 24, with a short selling balance of 0.00 yuan, indicating a high level compared to the 90th percentile over the past year [1]. Group 3 - For the period ending September 30, Anxu Bio reported a total revenue of 325 million yuan, a year-on-year decrease of 19.34%, and a net profit attributable to shareholders of 64.36 million yuan, down 52.60% year-on-year [2]. - The company has distributed a total of 895 million yuan in dividends since its A-share listing, with 657 million yuan distributed over the past three years [2]. - As of September 30, the number of shareholders increased to 6,090, while the average circulating shares per person decreased to 20,867 shares [2]. - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period [2].